GLAXO2021-04-012021-06-30in-bse-fin:OneOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares GLAXO 2021-04-01 2022-03-31 2021-07-06 INR Lakhs First quarter Single segment Pharmaceuticals 2021-04-01 2021-06-30 Unaudited Standalone 7734600000.00 317300000.00 8051900000.00 1671400000.00 1412900000.00 -135900000.00 1677900000.00 7900000.00 177100000.00 1601400000.00 6412700000.00 1639200000.00 0.00 1639200000.00 470000000.00 -34800000.00 435200000.00 0.00 1204000000.00 0.00 0.00 0.00 0.00 1204000000.00 0.00 1204000000.00 0.00 0.00 1694100000.00 10 7.11 7.11 0.00 0.00 7.11 7.11 0.00 0.00 0.00 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 26th July 2021. 2. The figures for the 3 months ended 31st March 2021 are the balancing figures between the audited figures in respect of full financial year and the year to date figures upto the third quarter of the financial year ended 31st March, 2021. 3. Other income for the quarter ended 30th June 2021 includes interest on income tax refund of Rs.2121 Lakhs (quarter ended 30th June 2020 Rs. 4268 Lakhs), year ended 31st March 2021 Rs.7129 lakhs and quarter ended 31st March 2021 Rs.2227 Lakhs respectively. 4. Exceptional items for the year ended 31st March 2021 Rs.17260 lakhs mainly comprise : a) impairment of INR 20900 lakhs net of reversal of associated costs and costs to sell to reflect the estimated realizable value of the Vemgal assets b) impacts of reversal of provision of Rs.3480 lakhs on account of Zinetac recall c) Profit on sale of a surplus property Rs. 184 lakhs Exceptional items for the quarter ended 31st March 2021 Rs.11900 lakhs mainly comprise: a) impairment of Rs. 12700 lakhs net of reversal of associated costs and costs to sell to reflect the estimated realizable value of the Vemgal assets b) impact of reversal of provision of Rs.800 lakhs on account of Zinetac recall 5. The Board of Directors ('Board') of the Company at their meeting held on 26th July 2021 approved: (a) transfer of the trademarks ‘pertaining to ‘Iodex’ and ‘Ostocalcium’ brands in India along with legal, economic, commercial and marketing rights of such brands and other associated assets to GlaxoSmithKline Asia Private Limited with respective values aggregating to INR 164901 lakhs. (b) acquisition of assets and liabilities associated with the vaccines business of GlaxoSmithKline Asia Private Limited for a consideration of INR 166 lakhs. The proposed transactions are subject to approval by the shareholders of the Company and customary regulatory approvals. Accordingly no effect has been given in this financial results for these proposed transactions. 6. The spread of Covid-19 is having an unprecedented impact on people and economy. The Company has considered the possible effects that may result from the pandemic relating to COVID-19 on the carrying amounts of trade receivables, tangible assets, intangible assets and investments. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the Company, as at the date of approval of these financial results has used internal and external sources of information. The impact assessment of Covid-19 is a continuing process given the uncertainties and the Company will continue to closely monitor the developments. 7. The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made. 8. Previous periods' figures have been re-grouped / re-classified wherever necessary. Other Expenses 1601400000.00